175 results
Page 9 of 9
424B5
s0wjp8nhk1ygfys7g
18 Mar 16
Prospectus supplement for primary offering
12:00am
6-K
EX-99.1
ywrclm5qo
27 Oct 15
Current report (foreign)
12:00am
6-K
EX-99.1
cd6zx9bnlxm
9 Oct 15
Appoints Former Aptalis and Novartis Executive, Theresa M. Stevens, as Chief Corporate Development Officer
12:00am
20-F
cor0d
31 Mar 15
Annual report (foreign)
12:00am
6-K
EX-99.1
lgcbqa7b90u7
2 Feb 15
Bio Blast Announces Key Leadership Changes
12:00am
6-K
EX-99.1
az98tbtexmh5q9
8 Jan 15
Current report (foreign)
12:00am
6-K
EX-99.1
w4oik f2d
17 Dec 14
BioBlast Receives Notice of Patent Issuance from USPTO for Its Novel Fusion Protein-Based Platform for the Treatment of Friedrich’s Ataxia
12:00am
6-K
EX-99.1
1qb2xb
21 Nov 14
Bio Blast Pharma Reports Third Quarter Financial Results
12:00am
6-K
EX-99.1
tunj5m 8p5
19 Nov 14
Bio Blast Pharma Receives Orphan Drug Designation
12:00am
6-K
EX-99.1
0mljfj9 mbdz
22 Sep 14
Bio Blast Pharma Announces Initiation of its Canadian OPMD Clinical Study Center at McGill University, Montreal
12:00am
6-K
EX-99.1
325av5 pe3
17 Sep 14
BioBlast Pharma Announces Preclinical and Clinical Pharmacokinetic Results with Cabaletta, Interim Safety Results from Phase 2/3HOPEMD Study in OPMD
12:00am
6-K
EX-99.1
fpg z72u1
29 Aug 14
BioBlast Pharma Reports Second Quarter Financial Results
12:00am
424B4
khtv2yaec cb
31 Jul 14
Prospectus supplement with pricing info
12:00am
F-1/A
lfnyy1r518oha j11
8 Jul 14
Registration statement (foreign) (amended)
12:00am
F-1/A
EX-3.2
kb14 ws53d8
8 Jul 14
Registration statement (foreign) (amended)
12:00am